One such clinically relevant senolytic is venetoclax, which is a small-molecule inhibitor of BCL2 used in the treatment of chronic lymphocytic leukemia and other hematologic malignancies [66,67]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.